Physician profile
Parvin Shafa
NPI 1447383559
$1,852.27
in general payments reported to CMS, 2019-2025
20 companies · $652 in 2025
The $652 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $243 · 2020: $199 · 2021: $40.96 · 2022: $61.48 · 2023: $282 · 2024: $375 · 2025: $652.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,308.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,308.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $241.02 | 2019-2025 | Nemluvio |
| Amgen INC. | $208.41 | 2024-2025 | Otezla, Otezla |
| Venclose INC. | $179.22 | 2020 | |
| Pfizer INC. | $162.72 | 2022-2024 | |
| New World Medical,INC. | $147.43 | 2025 | Streamline, Kahook Dual Blade, Ahmed Glaucoma Valve |
| Arcutis Biotherapeutics, INC. | $141.66 | 2023 | |
| Sun Pharmaceutical Industries INC. | $139.16 | 2019-2025 | |
| Revance Therapeutics, INC. | $129.56 | 2025 | Daxxify |
| Merz North America, INC. | $84.58 | 2019-2023 | Xeomin |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $78.97 | 2019 | |
| Incyte Corporation | $70.74 | 2023-2024 | Opzelura |
| Leo Pharma INC. | $68.45 | 2024-2025 | Anzupgo, Adbry |
| Lumenis, INC | $40.96 | 2021 | |
| Strata Skin Sciences, INC. | $34.40 | 2025 | Xtrac |
| Genzyme Corporation | $24.01 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $23.60 | 2025 | Cygnus Dual |
| Lilly USA, LLC | $22.16 | 2025 | Zepbound, Mounjaro |
| Solta Medical, A Division of Bausch Health US, LLC | $21.35 | 2025 | |
| Biofrontera INC. | $19.69 | 2020 | |
| Verrica Pharmaceuticals INC. | $14.18 | 2024 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parvin Shafa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.